Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies

Thromboembolism remains the second most common cause of death in cancer patients, with both cancer itself and certain cancer-directed therapies being well known risk factors for venous thromboembolism (VTE) [1]. Models integrating clinical risk factors for cancer-associated thrombosis (CAT) have identified patients that benefit from thromboprophylaxis, however well adopted models such as the Khorana risk score may have limited predictive ability for those receiving immune-checkpoint inhibitors [2].